Gene Defects and Mutant Alk Kinase in Human Solid Tumors
Cell Signaling Technology, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 9 of these applications claim priority to application 60/792,364, filed Apr 14, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,168,383 | Gene Defects and Mutant Alk Kinase in Human Solid Tumors In force · High confidence UsedRemaining | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 8,288,102 | Gene Defects and Mutant Alk Kinase in Human Solid Tumors In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 8,377,642 | Gene Defects and Mutant Alk Kinase in Human Solid Tumors In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 9,523,130 | Methods of Treating Non-Small Cell Lung Carcinoma (NSCLC) In force · Medium confidence | Cell Signaling Technology, Inc. | In force | Medium confidence | ||
| US 9,988,688 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 10,870,892 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 10,955,416 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Human Lung Cancer In force · Medium confidence | Cell Signaling Technology, Inc. | In force | Medium confidence | ||
| US 11,505,833 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| US 7,700,339 | Gene Defects and Mutant Alk Kinase in Human Solid Tumors In force · High confidence | Cell Signaling Technology, Inc. | In force | High confidence | ||
| Application 13/940,521 | Gene Defects And Mutant ALK Kinase In Human Solid Tumors Abandoned Abandoned Jul 21, 2017 | Cell Signaling Technology, Inc. | Abandoned | Abandoned Jul 21, 2017 | ||
| 1 more record in this group · Pro | ||||||
10 of 11 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 11, including 9 expiring within the 18 months from Nov 20, 2026.
9 of these are in force and held by Cell Signaling Technology, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.